Istari Oncology Hires Marc Banjak as General Counsel and Secretary as the Company Prepares for a Critical Period of Development and Expansion April 29, 2021 -- Istari Oncology, Inc., a clinical-stage biotechnology company today announced that Marc Banjak has joined…
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma Objective responses observed in patients’ refractory to programmed death receptor-1 (PD-1) inhibitors and BRAF-targeted therapy Responses in both injected and…
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors Istari clinical trial program expands to evaluate PVSRIPO in a range of solid tumors…
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO LUMINOS-101 and LUMINOS-103 study designs to be presented Expanding clinical trial program designed to…
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma DURHAM, NC, March 31, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today…
Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity Intratumoral PVSRIPO stimulates a specific inflammatory response dominated by type-I/III interferon (IFN)—crucial for effective antitumor T cell priming…
From the office of UConn Health: High-Profile Brain Tumor Trial Chooses UConn Health An immunotherapy derived from the polio virus has shown improved survival rates in early-phase trials in patients with an aggressive type of brain tumor known as glioblastoma.…
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma DURHAM, NC, January 10, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has…
Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma DURHAM, NC, November 30, 2020 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced the…
From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New Trial with PVSRIPO, a Viral-based Immunotherapy in Combination with Pembrolizumab for Patients with Recurrent GBM The two therapies may be able to generate a potent…